SB-612,111

Source: Wikipedia, the free encyclopedia.
SB-612,111
Clinical data
Other namesSB-612,111
Identifiers
  • (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol
JSmol)
  • CC1=CC=CC2=C1CC[C@@H](C[C@@H]2O)CN3CCC(CC3)C4=C(C=CC=C4Cl)Cl

  • CC1=C2CC[C@@H](C[C@@H](C2=CC=C1)O)CN3CCC(CC3)C4=C(C=CC=C4Cl)Cl
  • InChI=1S/C24H29Cl2NO/c1-16-4-2-5-20-19(16)9-8-17(14-23(20)28)15-27-12-10-18(11-13-27)24-21(25)6-3-7-22(24)26/h2-7,17-18,23,28H,8-15H2,1H3/t17-,23-/m0/s1 ☒N
  • Key:OHRDCQFCAWLDBP-SBUREZEXSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

SB-612,111 is an opioid receptor ligand which is a potent and selective antagonist for the nociceptin receptor (ORL-1), several times more potent than the older drug J-113,397.[1] It does not have analgesic effects in its own right, but prevents the development of hyperalgesia,[2] and also shows antidepressant effects in animal studies.[3]

See also

References

  1. S2CID 17504101
    .
  2. S2CID 8036750
    .
  3. S2CID 2557475
    .


Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=SB-612,111&oldid=1191995012"